Tafenoquine for the radical cure and prevention of malaria: the importance of testing for G6PD deficiency

Robert J Commons, James S McCarthy, Ric N Price, Robert J Commons, James S McCarthy, Ric N Price

No abstract available

Keywords: Anti-infective agents; Malaria.

Conflict of interest statement

Ric Price is a Wellcome Trust Senior Fellow in Clinical Science (200909).

Ric Price was on the expert panel for the tafenoquine licensing application at the US Federal Drug Administration and on the expert committee for the Australian Therapeutic Goods Administration. His travel expenses to the US were reimbursed by GlaxoSmithKline. James McCarthy received funding from 60 Degrees Pharmaceuticals to conduct a randomised controlled trial to test the activity of tafenoquine as a potential drug for the chemoprophylaxis of malaria.

References

    1. Baird JK. Primaquine toxicity forestalls effective therapeutic management of the endemic malarias. Int J Parasitol 2012; 42: 1049–1054.
    1. Baird JK. Tafenoquine for travelers’ malaria: evidence, rationale and recommendations. J Travel Med 2018; 25: tay100.
    1. Brueckner RP, Lasseter KC, Lin ET, Schuster BG. First‐time‐in‐humans safety and pharmacokinetics of WR 238605, a new antimalarial. Am J Trop Med Hyg 1998; 58: 645–649.
    1. Llanos‐Cuentas A, Lacerda MV, Rueangweerayut R, et al. Tafenoquine plus chloroquine for the treatment and relapse prevention of Plasmodium vivax malaria (DETECTIVE): a multicentre, double‐blind, randomised, phase 2b dose‐selection study. Lancet 2014; 383: 1049–1058.
    1. Chu CS, Freedman DO. Tafenoquine and G6PD: A Primer for Clinicians. J Travel Med 2019; 26: taz023.
    1. Shanks GD, Oloo AJ, Aleman GM, et al. A new primaquine analogue, tafenoquine (WR 238605), for prophylaxis against Plasmodium falciparum malaria. Clin Infect Dis 2001; 33: 1968–1974.
    1. Minucci A, Moradkhani K, Hwang MJ, et al. Glucose‐6‐phosphate dehydrogenase (G6PD) mutations database: review of the “old” and update of the new mutations. Blood Cells Mol Dis 2012; 48: 154–165.
    1. Chu CS, Bancone G, Nosten F, et al. Primaquine‐induced haemolysis in females heterozygous for G6PD deficiency. Malar J 2018; 17: 101.
    1. Antibiotic Expert Group . Therapeutic Guidelines: Antibiotic. Version 16. Melbourne: Therapeutic Guidelines, 2019. (viewed Dec 2019).
    1. World Health Organization . Guidelines for the treatment of malaria; 3rd ed Geneva: World Health Organization, 2015. (viewed Dec 2019).
    1. Bancone G, Gornsawun G, Chu CS, et al. Validation of the quantitative point‐of‐care CareStart biosensor for assessment of G6PD activity in venous blood. PLoS One 2018; 13: e0196716.
    1. Pal S, Bansil P, Bancone G, et al. Evaluation of a novel quantitative test for glucose‐6‐phosphate dehydrogenase deficiency: bringing quantitative testing for glucose‐6‐phosphate dehydrogenase deficiency closer to the patient. Am J Trop Med Hyg 2019; 100: 213–221.
    1. Ley B, Bancone G, von Seidlein L, et al. Methods for the field evaluation of quantitative G6PD diagnostics: a review. Malar J 2017; 16: 361.
    1. GlaxoSmithKline . Highlights of prescribing information: KRINTAFEL (tafenoquine). 2018. (viewed Feb 2019).
    1. Lacerda MVG, Llanos‐Cuentas A, Krudsood S, et al. Single‐dose tafenoquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med 2019; 380: 215–228.
    1. Llanos‐Cuentas A, Lacerda MVG, Hien TT, et al. Tafenoquine versus primaquine to prevent relapse of Plasmodium vivax malaria. N Engl J Med 2019; 380: 229–241.

Source: PubMed

Sponsors en medewerkers

Medische omstandigheden

Geneesmiddelinterventies

3
Abonneren